Literature DB >> 8866635

Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.

R A Lysaa1, T Giverhaug, H L Wold, J Aarbakke.   

Abstract

RESULTS: Incubation in vitro of human recombinant and erythrocyte (RBC) thiopurine methyl transferase (TPMT) with furosemide, bendroflumethiazide and trichlormethiazide demonstrated inhibition of both enzyme preparations, with IC50 values of 170 microM, 360 microM and 1 mM, respectively. Kinetic studies revealed that the inhibition was mixed or non-competitive with regard both to the thiopurine substrate 6-mercaptopurine (6-MP) and the methyl donor S-adenosyl-L-methionine.
CONCLUSION: Since S-methylation is a major pathway in the metabolism of thiopurines, our data point to the possibility of a clinically significant diuretic-thiopurine interaction in patients treated simultaneously with these drugs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866635     DOI: 10.1007/s002280050038

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients.

Authors:  P R Chocair; J A Duley; H A Simmonds; J S Cameron
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

2.  Biology and pharmacology of thiopurines.

Authors:  J Aarbakke
Journal:  Pediatr Hematol Oncol       Date:  1995 Sep-Oct       Impact factor: 1.969

3.  Absorption of high dose furosemide (frusemide) in congestive heart failure.

Authors:  J J Van Meyel; P G Gerlag; P Smits; F G Russel; Y Tan; C A Van Ginneken; F W Gribnau
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

4.  Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.

Authors:  C L Szumlanski; R M Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

5.  Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.

Authors:  R M Weinshilboum; F A Raymond; P A Pazmiño
Journal:  Clin Chim Acta       Date:  1978-05-02       Impact factor: 3.786

6.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

7.  Gender difference in red blood cell thiopurine methyltransferase activity.

Authors:  B Klemetsdal; E Wist; J Aarbakke
Journal:  Scand J Clin Lab Invest       Date:  1993-11       Impact factor: 1.713

8.  Erythrocyte fraction affects red blood cell thiopurine methyltransferase activity.

Authors:  B Klemetsdal; B Straume; R Lysaa; T Giverhaug; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA.

Authors:  R Honchel; I A Aksoy; C Szumlanski; T C Wood; D M Otterness; E D Wieben; R M Weinshilboum
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

10.  Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes.

Authors:  C L Szumlanski; R Honchel; M C Scott; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  1992-08
View more
  15 in total

1.  Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine.

Authors:  T Dervieux; Y Médard; V Baudouin; A Maisin; D Zhang; F Broly; C Loirat; E Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

Review 2.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

3.  Thiopurine S-methyltransferase as a target for drug interactions.

Authors:  Hua-Wen Xin; Christine Fischer; Matthias Schwab; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

4.  Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Authors:  Margalida Calafat; Míriam Mañosa; Fiorella Cañete; Eugeni Domènech
Journal:  Drugs Aging       Date:  2021-01-13       Impact factor: 3.923

Review 5.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 6.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  TPMT in the treatment of Crohn's disease with azathioprine.

Authors:  L Lennard
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

Review 8.  Therapeutic drug monitoring in patients with inflammatory bowel disease.

Authors:  Andres J Yarur; Maria T Abreu; Amar R Deshpande; David H Kerman; Daniel A Sussman
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

9.  Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs.

Authors:  Barbara Wusk; G A Kullak-Ublick; C Rammert; A von Eckardstein; M Fried; K M Rentsch
Journal:  Eur J Clin Pharmacol       Date:  2004-02-24       Impact factor: 2.953

Review 10.  Clinical pharmacology and pharmacogenetics of thiopurines.

Authors:  Srikumar Sahasranaman; Danny Howard; Sandip Roy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-28       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.